To the Editor We congratulate Binenbaum et al1 on their work on validation of postnatal growth and retinopathy of prematurity screening criteria. Safely reducing the number of infants requiring a retinopathy of prematurity (ROP) examination is challenging. We respectfully share some concerns about the statistical aspects of the article.
The Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) statement is a 22-item checklist for reporting on the development and validation of prediction models.2 In addition, important aspects for consideration of performance are discrimination (the C index) and calibration (a plot of expected outcome probabilities against observed outcome frequencies). Were all the TRIPOD recommendations used for developing3 or validating1 the model, since the report has sensitivity with confidence intervals as a performance measure?
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Raghuveer TS, Zackula RE, Okut H. Inquiries on the Validation of a Model to Reduce Retinopathy of Prematurity Testing. JAMA Ophthalmol. 2020;138(6):710–711. doi:10.1001/jamaophthalmol.2020.1129
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: